

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Acotec Scientific Holdings Limited
先瑞達醫療科技控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6669)

**SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT
FOR THE YEAR ENDED DECEMBER 31, 2022**

Reference is made to the annual report of Acotec Scientific Holdings Limited (the “**Company**”) for the year ended December 31, 2022 published on April 24, 2023 (the “**Annual Report**”). Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meaning as those defined in the Annual Report. In addition to the disclosure made by the Company in the Annual Report, the Company wishes to provide the following information in respect of the RSU Scheme and the Share Award Scheme of the Company.

RSU SCHEME

The table below shows details of the movements of cancelled, lapsed and forfeited restricted Shares granted to the Grantees under the RSU Scheme during the Reporting Period:

Grantees	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Forfeited during the Reporting Period
55 employees	–	–	60,000 ^{Note}
Two employees	–	–	–
Nine employees	–	–	–
Total	–	–	60,000

Note: The Company forfeited 60,000 granted restricted Shares for certain Grantees upon their resignation from the Company. For details, please refer to note 29(b) to the consolidated financial statements in the Annual Report.

SHARE AWARD SCHEME

Participants of the Share Award Scheme

The participants of the Share Award Scheme shall cover any individual, being:

- (i) an employee (whether full-time or part-time employee) of any member of the Group provided that the individual shall not cease to be an employee in the case of (a) any leave of absence approved by the relevant member of the Group; or (b) transfer amongst any member of the Group or any successor, and provided further that an employee shall, for the avoidance of doubt, cease to be an employee with effect from (and including) the date of termination of his employment; or
- (ii) a director of any member of the Group,

who the Board or any person authorized by the Board for the administration of the Share Award Scheme (the “**Authorized Person**”) (as the case may be) considers, in its sole discretion, to have contributed or will contribute to the Group.

However, no individual who is resident in a place where the grant, acceptance or vesting of an Award pursuant to the Share Award Scheme is not permitted under the laws and regulations of such place or where, in the view of the Board or an Authorized Person, compliance with applicable laws and regulations in such place makes it necessary or expedient to exclude such individual, shall be entitled to participate in the Share Award Scheme and such individual shall therefore be excluded.

Remaining Life of the Share Award Scheme

Unless terminated earlier as determined by the Board, the Share Award Scheme shall be valid and effective for the period commencing on the Adoption Date, and ending on the business day immediately prior to the 10th anniversary of the Adoption Date. At the end of the Reporting Period, the remaining life of the Share Award Scheme shall be approximately nine (9) years.

The above additional information does not affect the other information contained in the Annual Report. Save as disclosed above, all the other information in the Annual Report remain unchanged.

By Order of the Board
Acotec Scientific Holdings Limited
Jing LI

*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, September 6, 2023

As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Arthur Crosswell BUTCHER and Ms. June CHANG, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.